公开(公告)号：US20240156816A1

公开(公告)日：2024-05-16

申请号：US18541680

申请日：2023-12-15

Applicant: Massachusetts Institute of Technology ,  Dana-Farber Cancer Institute, Inc.

Inventor： Alexander K. Shalek ,  Peter Winter ,  David Weinstock ,  Mark Murakami ,  Scott Manalis ,  Andrew Navia ,  Jennyfer Galvez-Reyes

IPC: A61K31/506 ,  A61K31/403 ,  A61K31/427 ,  A61K31/44 ,  A61K31/5383 ,  A61K45/06 ,  A61P35/02 ,  C07K16/28

CPC classification number: A61K31/506 ,  A61K31/403 ,  A61K31/427 ,  A61K31/44 ,  A61K31/5383 ,  A61K45/06 ,  A61P35/02 ,  C07K16/2887

Abstract: Described in exemplary embodiments herein are methods, compositions, and kits for diagnosing, prognosing, monitoring, treating and/or preventing a hemopoietic malignancy and/or relapse thereof in a subject. In some embodiments, the methods can include determining an average cellular mass of cells in a sample from the subject and/or detecting one or more molecular signatures in one or more of the cells. In some embodiments, treatment includes administering one or more BCR-ABL tyrosine kinase inhibitors or a pharmaceutical formulation thereof, one or more pre-BCR signaling pathway inhibitors or a pharmaceutical formulation thereof, one or more p38 MAPK inhibitors or a pharmaceutical formulation thereof; or any combination thereof.

公开(公告)号：US20240156728A1

公开(公告)日：2024-05-16

申请号：US18454289

申请日：2023-08-23

Applicant: Pulmatrix Operating Company, Inc.

Inventor： Jean C. SUNG ,  Michael M. LIPP

IPC: A61K9/00 ,  A61K31/137 ,  A61K31/407 ,  A61K31/439 ,  A61K31/4745 ,  A61K31/496 ,  A61K31/5383 ,  A61K31/56 ,  A61K31/58 ,  A61K31/7036 ,  A61K38/00 ,  A61K38/28 ,  A61K39/00 ,  A61K39/395 ,  A61K47/02 ,  A61K47/18 ,  C07K16/00

CPC classification number: A61K9/0073 ,  A61K9/0075 ,  A61K31/137 ,  A61K31/407 ,  A61K31/439 ,  A61K31/4745 ,  A61K31/496 ,  A61K31/5383 ,  A61K31/56 ,  A61K31/58 ,  A61K31/7036 ,  A61K38/00 ,  A61K38/28 ,  A61K39/00 ,  A61K39/395 ,  A61K47/02 ,  A61K47/183 ,  C07K16/00

Abstract: The present invention is directed toward respirable dry powders and particles for systemic delivery of pharmaceutically active agents or delivery to the respiratory tract. The dry powders contain one or more monovalent metal cations (such as Na+), are small and dispersible.

公开(公告)号：US11974998B2

公开(公告)日：2024-05-07

申请号：US18366060

申请日：2023-08-07

Applicant: BOW RIVER LLC

Inventor： Sundar Srinivasan ,  Christina Chow Wallen

IPC: A61K31/496 ,  A61K9/00 ,  A61K9/08 ,  A61K9/10 ,  A61K9/20 ,  A61K9/48 ,  A61K31/00 ,  A61K31/397 ,  A61K31/407 ,  A61K31/4468 ,  A61K31/454 ,  A61K31/4745 ,  A61K31/497 ,  A61K31/498 ,  A61K31/4995 ,  A61K31/502 ,  A61K31/506 ,  A61K31/519 ,  A61K31/5383 ,  A61K31/5395 ,  A61P25/16 ,  A61P25/18 ,  A61P35/00 ,  A61P35/02 ,  A61P35/04

CPC classification number: A61K31/496 ,  A61K9/0019 ,  A61K9/0053 ,  A61K9/0056 ,  A61K9/0078 ,  A61K9/0095 ,  A61K9/08 ,  A61K9/10 ,  A61K9/2004 ,  A61K9/4841 ,  A61K31/00 ,  A61K31/397 ,  A61K31/407 ,  A61K31/4468 ,  A61K31/454 ,  A61K31/4745 ,  A61K31/497 ,  A61K31/498 ,  A61K31/4995 ,  A61K31/502 ,  A61K31/506 ,  A61K31/519 ,  A61K31/5383 ,  A61K31/5395 ,  A61P25/16 ,  A61P25/18 ,  A61P35/02 ,  A61P35/04

Abstract: The present disclosure provides for methods of treating a patient with a CYP3A4 substrate drug, wherein the patient is treated with posaconazole. In some embodiments, the patient stops posaconazole treatment, waits for at least 3 days, and then is treated with the CYP3A4 substrate drug as soon as it is safe to do so. In some embodiments, treatment with the CYP3A4 substrate drug is delayed for about 3-42 days after stopping posaconazole. In some embodiments, the patient is treated with a reduced dose of the CYP3A4 substrate drug for about 3-42 days.

公开(公告)号：US20240108734A1

公开(公告)日：2024-04-04

申请号：US18273716

申请日：2022-01-21

Applicant: The Regents of the University of California

Inventor： Catriona JAMIESON ,  Wenxue MA

IPC: A61K47/54 ,  A61K9/127 ,  A61K31/365 ,  A61K31/506 ,  A61K31/519 ,  A61K31/5383 ,  A61K31/635 ,  A61K31/7064 ,  A61K35/28 ,  A61K38/50 ,  A61K45/06 ,  A61M15/08 ,  A61P31/14 ,  A61P31/16 ,  A61P35/02 ,  C12N15/113 ,  C12N15/86

CPC classification number: A61K47/549 ,  A61K9/127 ,  A61K31/365 ,  A61K31/506 ,  A61K31/519 ,  A61K31/5383 ,  A61K31/635 ,  A61K31/7064 ,  A61K35/28 ,  A61K38/50 ,  A61K45/06 ,  A61M15/08 ,  A61P31/14 ,  A61P31/16 ,  A61P35/02 ,  C12N15/1137 ,  C12N15/86 ,  C12Y305/04 ,  C12N2310/14 ,  C12N2310/531 ,  C12N2740/15043

Abstract: In alternative embodiments, provided are methods for treating and ameliorating a cancer such as a leukemia such as acute myeloid leukemia (AML) comprising administration to an individual in need thereof a pharmaceutical composition comprising imetelstat, or imetelstat and second drug such as dasatinib, or ruxolitinib, fedratinib, 8-aza-adenosine, raltegravir and/or dolutegravir or any combination thereof. In alternative embodiments, provided are methods for the in vivo inhibition of myeloproliferative neoplasm (MPN) or AML stem cell propagation comprising administration to an individual in need thereof a pharmaceutical composition comprising imetelstat, or imetelstat and second drug. In alternative embodiments, provided are methods for the in vivo inhibition pre-leukemia stem cell (pre-LSC) transformation into leukemia stem cells (LSCs) comprising administration to an individual in need thereof a pharmaceutical composition comprising imetelstat, or imetelstat and second drug such as dastinib, or ruxolitinib, fedratinib, 8-aza-adenosine, raltegravir and/or dolutegravir or any combination thereof.

公开(公告)号：US20240041871A1

公开(公告)日：2024-02-08

申请号：US18481170

申请日：2023-10-04

Applicant: INTRA-CELLULAR THERAPIES, INC.

Inventor： Sharon MATES ,  Allen FIENBERG ,  Lawrence P. WENNOGLE

IPC: A61K31/4985 ,  C07D471/14 ,  C07D498/14 ,  A61K31/44 ,  A61K31/5383 ,  A61K9/00 ,  A61K31/198 ,  A61K45/06

CPC classification number: A61K31/4985 ,  C07D471/14 ,  C07D498/14 ,  A61K31/44 ,  A61K31/5383 ,  A61K9/0053 ,  A61K31/198 ,  A61K45/06

Abstract: Use of particular substituted heterocycle fused gamma-carboline compounds as pharmaceuticals and pharmaceutical compositions comprising them for the treatment of one or more disorders involving the 5-HT2A, SERT and/or dopamine D2 pathways are disclosed. In addition, the compounds may be combined with other therapeutic agents for the treatment of one or more sleep disorders, depression, psychosis, dyskinesias, and/or Parkinson's disease or any combinations.

公开(公告)号：US11865225B2

公开(公告)日：2024-01-09

申请号：US17057924

申请日：2020-11-06

Applicant: GCS Co., Ltd.

Inventor： Chang Sik Kim

IPC: A61L27/26 ,  A61K9/50 ,  A61L27/54 ,  A61K9/00 ,  A61K9/16 ,  A61K31/167 ,  A61K31/4178 ,  A61K31/431 ,  A61K31/445 ,  A61K31/496 ,  A61K31/5383 ,  A61K31/665 ,  A61K31/7036 ,  A61K31/7056 ,  A61L27/58

CPC classification number: A61L27/26 ,  A61K9/5031 ,  A61K9/5036 ,  A61K9/5073 ,  A61K9/5089 ,  A61K31/167 ,  A61K31/4178 ,  A61K31/431 ,  A61K31/445 ,  A61K31/496 ,  A61K31/5383 ,  A61K31/665 ,  A61K31/7036 ,  A61K31/7056 ,  A61L27/54 ,  A61L27/58 ,  A61L2300/406 ,  A61L2300/622

Abstract: Disclosed are a sustained-release injection formulation containing a biodegradable polymer double microcapsule that contains a conjugate of poly-L-lactic acid (hereinafter referred to as “PLLA”) filler and hyaluronic acid (hereinafter referred to as “HA”) and is capable of controlling the release rate of PLLA, and a method of preparing the same.

公开(公告)号：US11850213B2

公开(公告)日：2023-12-26

申请号：US17098272

申请日：2020-11-13

Applicant: AMD THERAPEUTICS LLC

Inventor： Hiroaki Serizawa

IPC: A61K31/5383 ,  A61K31/496 ,  A61K9/00 ,  A61K9/08 ,  A61K31/435 ,  A61K47/02 ,  A61K47/10 ,  A61K47/14 ,  A61K47/26

CPC classification number: A61K31/5383 ,  A61K9/0048 ,  A61K9/08 ,  A61K31/435 ,  A61K31/496 ,  A61K47/02 ,  A61K47/10 ,  A61K47/14 ,  A61K47/26

Abstract: Provided herein are ophthalmic pharmaceutical formulations comprising a rifamycin compound. Also provided herein are methods of treating ocular diseases or disorders by administering such ophthalmic formulations.

公开(公告)号：US11844800B2

公开(公告)日：2023-12-19

申请号：US17085650

申请日：2020-10-30

Applicant: Massachusetts Institute of Technology ,  Dana-Farber Cancer Institute, Inc.

Inventor： Alexander K. Shalek ,  Peter Winter ,  David Weinstock ,  Mark Murakami ,  Scott Manalis ,  Andrew Navia ,  Jennyfer Galvez-Reyes

IPC: A61K31/506 ,  C07K16/28 ,  A61K45/06 ,  A61K31/403 ,  A61K31/427 ,  A61K31/5383 ,  A61K31/44 ,  A61P35/02

CPC classification number: A61K31/506 ,  A61K31/403 ,  A61K31/427 ,  A61K31/44 ,  A61K31/5383 ,  A61K45/06 ,  A61P35/02 ,  C07K16/2887

Abstract: Described in exemplary embodiments herein are methods, compositions, and kits for diagnosing, prognosing, monitoring, treating and/or preventing a hemopoietic malignancy and/or relapse thereof in a subject. In some embodiments, the methods can include determining an average cellular mass of cells in a sample from the subject and/or detecting one or more molecular signatures in one or more of the cells. In some embodiments, treatment includes administering one or more BCR-ABL tyrosine kinase inhibitors or a pharmaceutical formulation thereof, one or more pre-BCR signaling pathway inhibitors or a pharmaceutical formulation thereof, one or more p38 MAPK inhibitors or a pharmaceutical formulation thereof; or any combination thereof.

公开(公告)号：US20230390301A1

公开(公告)日：2023-12-07

申请号：US18034200

申请日：2021-10-27

Applicant: ADLAI NORTYE BIOPHARMA CO., LTD.

Inventor： Yufeng CHEN ,  Peng WU ,  Meng LV ,  Canfeng LIU ,  Han YANG ,  Kaixuan CHEN ,  Wanli CHENG ,  Feifan LI ,  Youping WANG ,  Keke CHEN ,  Pingping LU ,  Nanhai HE

IPC: A61K31/551 ,  A61K31/519 ,  A61P35/00 ,  A61K31/5383 ,  A61K31/527

CPC classification number: A61K31/551 ,  A61K31/519 ,  A61P35/00 ,  A61K31/5383 ,  A61K31/527

Abstract: Provided are a compound having the structure of formula (I) for inhibiting Wnt pathway activity, a pharmaceutical composition comprising the compound, and use of the compound in prevention and/or treatment of cancers, tumors, inflammatory diseases, autoimmune diseases, or immune-mediated diseases.

公开(公告)号：US11801245B2

公开(公告)日：2023-10-31

申请号：US17949889

申请日：2022-09-21

Applicant: BOW RIVER LLC

Inventor： Sundar Srinivasan ,  Christina Chow Wallen

IPC: A61K31/496 ,  A61K31/498 ,  A61P35/02 ,  A61P25/18 ,  A61P25/16 ,  A61P35/04 ,  A61K9/00 ,  A61K9/08 ,  A61K9/10 ,  A61K9/20 ,  A61K9/48 ,  A61K31/00 ,  A61K31/397 ,  A61K31/407 ,  A61K31/4468 ,  A61K31/454 ,  A61K31/4745 ,  A61K31/497 ,  A61K31/4995 ,  A61K31/506 ,  A61K31/519 ,  A61K31/5383 ,  A61K31/5395

CPC classification number: A61K31/496 ,  A61K9/0019 ,  A61K9/0053 ,  A61K9/0056 ,  A61K9/0078 ,  A61K9/0095 ,  A61K9/08 ,  A61K9/10 ,  A61K9/2004 ,  A61K9/4841 ,  A61K31/00 ,  A61K31/397 ,  A61K31/407 ,  A61K31/4468 ,  A61K31/454 ,  A61K31/4745 ,  A61K31/497 ,  A61K31/498 ,  A61K31/4995 ,  A61K31/506 ,  A61K31/519 ,  A61K31/5383 ,  A61K31/5395 ,  A61P25/16 ,  A61P25/18 ,  A61P35/02 ,  A61P35/04

Abstract: The present disclosure provides for methods of treating a patient with a CYP3A4 substrate drug, wherein the patient is treated with posaconazole. In some embodiments, the patient stops posaconazole treatment, waits for at least 2 days, and then is treated with the CYP3A4 substrate drug as soon as it is safe to do so. In some embodiments, treatment with the CYP3A4 substrate drug is delayed for about 2-42 days after stopping posaconazole. In some embodiments, the patient is treated with a reduced dose of the CYP3A4 substrate drug for about 2-42 days.